Loading
Pooling two trials, imatinib shrank tumours in about half of patients with locally advanced or metastatic dermatofibrosarcoma protuberans, confirming that blocking the PDGF receptor works in this fusion-driven sarcoma.
Pooled analysis of 24 patients with locally advanced or metastatic dermatofibrosarcoma protuberans treated with imatinib in the EORTC 62027 (800 mg) and SWOG S0345 (400 mg) phase 2 trials, both closed early for slow accrual.
Objective response was 46 percent, with median time to progression of 1.7 years, and responses were similar at both doses; tumours with fibrosarcomatous transformation also responded.
Imatinib is the standard systemic treatment for unresectable, recurrent or metastatic dermatofibrosarcoma protuberans and is used neoadjuvantly to shrink large tumours before surgery.
Shares Imatinib, Journal of Clinical Oncology.
Shares Imatinib, Journal of Clinical Oncology.
Shares Dermatofibrosarcoma protuberans, Imatinib.
Shares Imatinib, Journal of Clinical Oncology.
Shares Imatinib, Journal of Clinical Oncology.
Shares Dermatofibrosarcoma protuberans, Imatinib.
Shares Dermatofibrosarcoma protuberans, Imatinib.
Shares Piotr Rutkowski, Dermatofibrosarcoma protuberans, Imatinib.